C

CureVac NV
D

CVAC

5.43500
USD
-0.07
(-1.18%)
Market Closed
Volume
114,026
EPS
-0
Div Yield
-
P/E
6
Market Cap
1,223,741,132
Related Instruments
AZN
AZN
-0.800
(-1.13%)
69.950 USD
BNTX
BNTX
2.140
(2.05%)
106.620 USD
GSK
GSK
-0.595
(-1.54%)
38.045 USD
I
INO
0.01500
(0.77%)
1.95500 USD
JNJ
JNJ
-0.970
(-0.64%)
149.760 USD
MRNA
MRNA
0.510
(2.01%)
25.920 USD
N
NVAX
0.11500
(1.83%)
6.41500 USD
PFE
PFE
0.085
(0.36%)
23.970 USD
S
SVA
0
(0.00%)
0 USD
More
News

Title: CureVac NV

Sector: Healthcare
Industry: Biotechnology
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.